Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Ovarian Neoplasms 54Breast Neoplasms 37Fallopian Tube Neoplasms 22Multiple Myeloma 19Carcinoma, Ovarian Epithelial 15Neoplasms 12Lymphoma 10Triple Negative Breast Neoplasms 7Neoplasm Metastasis 6Lymphoma, Large B-Cell, Diffuse 6Recurrence 5Hodgkin Disease 4Breast Neoplasms, Male 4Solid Tumors 3Prostatic Neoplasms 3Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Anaplastic 3Burkitt Lymphoma 3Sarcoma, Kaposi 2Sarcoma 2Peritoneal Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2

Interventions

Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2siplizumab 1liposomal doxorubicin 1Vorinostat 1Salvia hispanica seed extract 1Rituximab 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Subcutaneous panniculitis-like T-cell lymphoma × liposomal doxorubicin × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡